All In Biotech

Drug Trial Radar · NCT06626919

Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-Oncology Plasma Cell-Related Diseases

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Apr 30, 2025

Primary completion

Oct 2028

Study completion Oct 2028

Sponsor

Lead sponsor
Kite, A Gilead CompanyGilead Sciences (GILD)
Sponsor type
Industry
First posted
Oct 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the study drug Anitocabtagene autoleucel (anito-cel), and its safety, tolerability, dosing, and preliminary effectiveness in participants with generalized myasthenia gravis (GMG). Anito-cel is a B-cell maturation antigen (BCMA)-directed CAR-T cell therapy. The primary objective of this study is to assess the safety profile, including any dose-limiting toxicity (DLT) and identification of a maximum tolerated dose (MTD) (if applicable), to support selection of the recommended Phase 2 dose (RP2D) of anito-cel when administered to participants with GMG.

Conditions

  • Muscular Diseases
  • Neuromuscular Manifestations
  • Autoimmune
  • Autoimmune Diseases
  • Autoimmune Diseases of the Nervous System
  • Myasthenia Gravis
  • Muscle Weakness

Interventions

  • anito-celBiological

    Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain

  • CyclophosphamideDrug

    Administered intravenously

  • FludarabineDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAE)Time frame: First dose date up to 24 months
  2. Percentage of Participants Experiencing Dose-Limiting Toxicities (DLT)Time frame: Up to 28 days following anito-cel infusion
  3. Maximum Tolerated Dose (MTD) of Anito-celTime frame: First dose up to 30 days (Up to 24 months)
  4. Percentage of Participants With Laboratory AbnormalitiesTime frame: First dose date up to 24 months
  5. Recommended Phase 2 Dose (RP2D) of Anito-celTime frame: Up to 24 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California · Recruiting

  • UC Irvine Medical Center

    Orange, California · Recruiting

  • Stanford Blood and Marrow Transplant

    Palo Alto, California · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • University of South Florida - Carol and Frank Morsani Center for Advanced Healthcare

    Tampa, Florida · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • University of Minnesota Delaware Clinical Research Unit

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Lewis Katz School of Medicine at Temple University

    Philadelphia, Pennsylvania · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Houston Methodist Hospital

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.